Publications by authors named "Mark K I Tan"
Objectives: Epidemiological and whole-genome sequencing analysis of an ongoing outbreak of Streptococcus pyogenes (Group A Streptococcus) in London (United Kingdom).
Methods: Prospective identification of Group A Streptococcus cases from a diagnostic laboratory serving central and south London between 27 November and 10 December 2022. Case notes were reviewed and isolates were retrieved.
Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: Results from a pilot service implemented during the first pandemic wave.
PLoS One
April 2021
During the first wave of the global COVID-19 pandemic the clinical utility and indications for SARS-CoV-2 serological testing were not clearly defined. The urgency to deploy serological assays required rapid evaluation of their performance characteristics. We undertook an internal validation of a CE marked lateral flow immunoassay (LFIA) (SureScreen Diagnostics) using serum from SARS-CoV-2 RNA positive individuals and pre-pandemic samples.
View Article and Find Full Text PDFArticle Synopsis
- Antibody responses to SARS-CoV-2 usually appear in most infected individuals within 10-15 days after symptoms start, but it's unclear how long they last or if they protect against reinfection.
- The study analyzed serum samples from 65 confirmed cases over 94 days and found that over 95% of individuals developed various antibody types, with neutralizing antibodies detected after 8 days post-symptom onset.
- Results indicated that while some individuals retained high neutralizing antibody levels for more than 60 days, others experienced a significant decline, suggesting that booster vaccinations may be necessary for sustained protection against COVID-19.